A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3. [electronic resource]
Producer: 20150629Description: 877-86 p. digitalISSN:- 1873-734X
- Adenocarcinoma -- genetics
- Adenocarcinoma of Lung
- Antineoplastic Agents -- pharmacology
- Basic Helix-Loop-Helix Transcription Factors -- genetics
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- E2F1 Transcription Factor -- genetics
- Genetic Therapy -- methods
- Humans
- Hypoxia-Inducible Factor 1 -- genetics
- Inhibitor of Apoptosis Proteins -- genetics
- Lung Neoplasms -- genetics
- Methotrexate -- pharmacology
- RNA Interference
- RNA, Small Interfering -- administration & dosage
- STAT3 Transcription Factor -- genetics
- Serum Response Factor -- genetics
- Survivin
- Transfection -- methods
- Vinblastine -- analogs & derivatives
- Vinorelbine
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.